Continuous disclosure obligations cause difficulties for many listed organisations. These difficulties are further amplified in the life sciences sector where entities need to communicate complex scientific information to investors and are faced with long regulatory and reimbursement timelines making determinations on how and when to disclose information to the market, under ASX Listing Rule 3.1 more challenging.
These challenges drove the development of the 'Code of Best Practice for Reporting by Life Science Companies' (the Code) by ASX, Ausbiotech and other key representatives in the life science sector.
Life science entities should closely follow the Code as it focuses on the key drivers of value for the sector, providing a recommended disclosure framework.
What are a listed company's legal obligations for disclosure?
ASX Listing Rule 3.1 requires that entities immediately disclose market sensitive information that a reasonable person would expect to have a material effect on the price or value of the entity's securities.
Market Sensitive Information
Like all ASX-listed entities, life science entities must objectively assess what information would likely influence an individual who commonly invests in securities to acquire or dispose their securities. The Code provides extensive (but not exhaustive) examples that are relevant for life science companies.
Once market sensitive information becomes known to the life science entity they must immediately disclose it (unless an exception applies).
"Immediately" means in a prompt manner without delay. Life science entities should prepare for this by establishing a subcommittee of the board with delegated authority to release disclosures to the market. This is particularly important where speculation or inaccurate reports are published on social media and online platforms and the entity needs to correct the market.
Life science entities should also make use of trading halts to respond to unexpected events, when faced with an evolving situation (such as a deal that is under negotiation and close to signing) or where there is a large volume of complex material to analyse (such as clinical trial results).
Neuren Pharmaceuticals faced the challenge of "immediate" disclosure part way through a Phase 2 trial of a drug treating Rett Syndrome, when patients' parents commented on social media about their perceptions of the positive effect of the drug on their children. Neuren Pharmaceuticals promptly requested a trading halt and then later in the day issued a clarification statement that the "double blind" nature of the trial had not been compromised and that the actual results would only be known at the end of the trial.
Life science entities must contemplate what information an independent and prudent individual would expect to be disclosed. It is essential that entities do not "cherry pick" by over-emphasising positive information while downplaying or obscuring negative information. This is especially important when reporting on clinical trials. Entities must disclose the results of the trials regardless of their outcome, because that information will certainly have a material effect on the value of the securities.
Exceptions to ASX Listing Rule 3.1
A life science entity does not need to disclose information when these three requirements are fulfilled:
- At least one of these applies;
- it would be a breach of law to disclose the information;
- the information concerns an incomplete proposal or negotiation;
- the information comprises matters of supposition or is insufficiently definite to warrant disclosure;
- the information is generated for the internal management purposes of the entity; or
- the information is a trade secret;
- the information is confidential and the ASX has not formed the view that the information has ceased to be confidential; and
- a reasonable person would not expect the information to be disclosed.
If at any time one of these ceases to apply, the entity must immediately disclose.
How does the Code assist?
The Code is a non-binding guideline for life science entities to use as a practical resource in applying the legal requirements of Listing Rule 3.1.
It promotes clear, timely and accurate market disclosures around key drivers of value for life science entities. Here is a summary of some of the guidelines:
|Research and Development Activities||
|Regulatory and Reimbursement Matters||
|Intellectual Property and Regulatory Exclusivity Rights||
|Licensing and other agreements of Commercial Significance||
|Key Staff Appointments and Departures||
Applying the Code
Life science entities need to recognise that the investors (both retail and institutional) may struggle to understand the entity's operations and strategy given the complexity of scientific information and long timelines in achieving regulatory and reimbursement milestones. By applying relevant guidance from the Code, a listed life science entity can strengthen its continuous disclosure practices, and the clarity of disclosures. This will promote informed and engaged investors and reduce the risk to the board of breaching the law.
Dentons is the world's first polycentric global law firm. A top 20 firm on the Acritas 2015 Global Elite Brand Index, the Firm is committed to challenging the status quo in delivering consistent and uncompromising quality and value in new and inventive ways. Driven to provide clients a competitive edge, and connected to the communities where its clients want to do business, Dentons knows that understanding local cultures is crucial to successfully completing a deal, resolving a dispute or solving a business challenge. Now the world's largest law firm, Dentons' global team builds agile, tailored solutions to meet the local, national and global needs of private and public clients of any size in more than 125 locations serving 50-plus countries. www.dentons.com.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.